CEA (antigène carcinoembrionique) — Surveillance post-traitement du CRC
Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.
| ID | BIO-CEA-CRC-MONITORING |
|---|---|
| Type | Biomarqueur |
| Alias | CEACEACAM5Antigène carcinoembrioniqueРЕА (раково-ембріональний антиген) — нагляд після лікування КРР |
| État | reviewed 2026-05-18 | pending_clinical_signoff |
| Maladies | Aucune déclaration |
| Sources | SRC-ESMO-CRC-2024 SRC-NCCN-COLON-2025 |
Données biomarqueurs
| Type de biomarqueur | serum_marker |
|---|---|
| Mesure | MéthodeImmunodosage sérique (ECLIA, CLIA) Unitésng/mL Échelle type
|
| Biomarqueurs connexes | Aucune déclaration |
Notes
Serum tumor marker (CEACAM5). NOT recommended for general-population CRC screening (low sensitivity for early-stage disease, false positives from smoking, IBD, cirrhosis, pancreatitis). PRIMARY surveillance use: after curative-intent resection of stage II/III CRC — q3-6 months CEA for 2 years then q6 months for 3-5 years (NCCN/ESMO concordant), rising trend triggers imaging workup for recurrence. Two consecutive rises >5 ng/mL or doubling within 1-2 months warrant CT chest/abdomen/pelvis and consider colonoscopy. Approximately 30% of CRCs do not secrete CEA (microsatellite-unstable, mucinous, signet-ring histologies); in those patients CEA surveillance has limited yield. Distinct from BIO-CTDNA-MRD which offers higher analytic sensitivity for molecular residual disease. STUB pending two-Co-Lead signoff.
Utilisé par
No reverse references found in the YAML corpus.